Bharat Biotech’s intra-nasal vaccine approved as primary, heterologous booster
iNCOVACC becomes the world’s first intranasal vaccine to receive both primary series and heterologous booster approval.
iNCOVACC becomes the world’s first intranasal vaccine to receive both primary series and heterologous booster approval.